30Jun 2022
Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies

To examine the efficacy of glucose‐lowering medications in subgroups of patients with type 2 diabetes mellitus (T2DM). Distinct metabolic phenotypes characterize different T2DM clusters and differential responses to glucose‐lowering therapies. For example, participants with severe insulin deficiency respond better to agents that preserve beta‐cell function, while, surprisingly, patients with severe insulin resistance did not respond favorably to insulin sensitizers.

  • #endo-diabetology

Like

Save

Share